Announcement of obtaining a license for manufacturing regenerative medicine products by Nikon CeLL innovation Co., Ltd.

April 14, 2020

TOKYO - Nikon CeLL innovation Co., Ltd. (Nikon CeLL innovation), wholly-owned subsidiary of Nikon Corporation (Nikon) obtained a license for manufacturing regenerative medicine products based on the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices on April 8, 2020.

Nikon CeLL innovation which was established in 2015 for dedicating to regenerative medicine contract manufacturing, has provided a wide range of process development and manufacturing services from pre-clinical to commercial manufacturing of cell and gene therapies.

At our facility in Koto-ku, Tokyo, we have been operating a contract development facility since 2016 and a contract manufacturing facility since 2017. In October 2019, Nikon CeLL innovation obtained a license as a cell processor based on the Act on the Safety of Regenerative Medicine, which is used by medical institutions such as university hospitals in pre-clinical and medical care outside health insurance of regenerative medicine.

Obtaining a license for manufacturing regenerative medicine products is an important milestone towards the practical use of regenerative medicine. Nikon and Nikon CeLL Innovation will promote the establishment of new treatments for diseases currently without effective treatments. Furthermore, we will develop practical applications for regenerative medicine and participate in the expansion of related industries.

The information is current as of the date of publication. It is subject to change without notice.